Zobrazeno 1 - 10
of 23
pro vyhledávání: '"R, Campestri"'
Publikováno v:
HemaSphere. 3:838-839
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92b609a4536a2849f070d9f4d83adead
https://doi.org/10.1097/01.hs9.0000565836.37777.8c
https://doi.org/10.1097/01.hs9.0000565836.37777.8c
Autor:
Carolina Bárbara Belli, Maria Virginia Prates, N. Pintos, M. Iastrebner, J. Posse Cobarco, Maria Marta Rivas, M. Cabrejo, M. Narbaitz, Jorge Arbelbide, E. Viñuales, D. Espinosa, Ana Lisa Basquiera, Graciela Alfonso, R. Campestri, V. Fernandez, J. Gonzalez, C. Lazzarino, Sofía Grille, Renée Crisp
Publikováno v:
Leukemia Research. 55:S59
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7cbac3eca8ad8ba9edb25b53a46d0240
https://doi.org/10.1016/s0145-2126(17)30208-4
https://doi.org/10.1016/s0145-2126(17)30208-4
Autor:
Viviana Ritacco, Javier Altclas, Claudia Salgueira, V. Brennan, Domingo Palmero, A. Lescano, R. Campestri, A. Di Martino
Publikováno v:
Transplant infectious disease : an official journal of the Transplantation Society. 7(1)
Multidrug-resistant tuberculosis (TB) is an increasing problem worldwide, however only three cases have been previously described in transplant recipients, especially involving lung and heart transplant. We describe a case of multidrug-resistant TB i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf216bd7887f93f3e848f3dbc55a5542
https://pubmed.ncbi.nlm.nih.gov/15984950
https://pubmed.ncbi.nlm.nih.gov/15984950
Autor:
L. Caicedo, G. Flores, R. Campestri, M. Iastrebner, M. Cabrejo, M.V. Prates, J. Arbelbide, I. Santos, P. Fazio, M. Rivas, F. Sackmann, Carolina Bárbara Belli, M. Agra, M. Ventriglia
Publikováno v:
Leukemia Research. 33:S63-S64
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e13b3fac4269a4b81fff867ffeb3ebd
https://doi.org/10.1016/s0145-2126(09)70090-6
https://doi.org/10.1016/s0145-2126(09)70090-6
Publikováno v:
Medicina. 59(3)
Multiple sclerosis (MS) is an autoimmune demyelinating disease exhibiting great clinical variability. For control of its primary and secondary progressive variants, treatment has met with limited success. In recent years, increasing experience has be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::87c5c7dc0ba6d16e38b29bc5ad7616e2
https://pubmed.ncbi.nlm.nih.gov/10451571
https://pubmed.ncbi.nlm.nih.gov/10451571
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Graciela Alfonso, M. Rivas, Ana Lisa Basquiera, H. Garcia Rivello, M.G. Flores, R. Campestri, F. Sackman, M.V. Prates, M. Cabrejo, P. Fazio, J. Alberbide, L. Kornblihtt
Publikováno v:
Leukemia Research. 35:S61
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a634fec33dad3d4f8f253e62c089dd3b
https://doi.org/10.1016/s0145-2126(11)70158-8
https://doi.org/10.1016/s0145-2126(11)70158-8
Publikováno v:
Journal of acquired immune deficiency syndromes. 3(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::caa9dde648bc0410d449fbf197d66258
https://pubmed.ncbi.nlm.nih.gov/2352127
https://pubmed.ncbi.nlm.nih.gov/2352127
Autor:
G. Stemmelin, Gustavo Milone, Sergio Giralt, E. Lanari, R. Bezares, J. García, D. Argentieri, M. Bartomioli, R. Campestri, E. Guy-Garay
Publikováno v:
Journal of Clinical Oncology. 24:6600-6600
6600 Background: Alemtuzumab is the only immunotherapy that is effective as a single agent in patients with B-CLL who are refractory to, or who have relapsed after, fludarabine therapy. The optimized schedule for alemtuzumab that achieves maximal eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::318daabd496be955b7b8f50c16daa0da
https://doi.org/10.1200/jco.2006.24.18_suppl.6600
https://doi.org/10.1200/jco.2006.24.18_suppl.6600
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.